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Challenges in Stem Cell Therapy: Bench-To-Bedside 
Varunkumar G. Pandey & Michael Karsy 
Since, the isolation of human embryonic stem (hESCs) cells by Thomson et al. in 1998, stem cell 
research has been recognized as the most promising component of the regenerative medicine.1  Stem 
cells are capable of differentiating into any cell type of the body and this pluripotency allows for        
limitless therapeutic potential.  However, the utility of hESCs is restricted because of pertinent ethical 
issues, limited availability of human blastocysts, and  possible allograft rejection. Furthermore, our    
understanding of cellular differentiation and epigenetic regulation are still in the primitive stages and 
pose major hurdles in stem cell research.  Before stem cell therapy can become a clinical reality, it is 
imperative that we address critical issues relating to programming efficiency, tumor susceptibility, and 
graft survival and rejection.  Nonetheless, commendable milestones have been already achieved in the 
study of stem cells by a number of research groups, and regenerative medicine is gradually inching    
towards a plausible reality of stem cell therapy.  The FDA has recently approved the usage of a hESC-
based therapy in 2010 where clinical trials have been initiated by Geron Corporation for patients with 
spinal cord injury.  In this article, we appreciate the recent advancements in stem cell research and      
discuss current challenges faced by various research groups in stem cell  research.   
The discovery of induced pluripotent stem cells (iPSCs) has paved a new paradigm in stem cell re-
search.  The exemplary ingenuity of Shinya Yamanaka in developing a cellular  reprogramming        
technology that facilitates production of iPSCs from somatic cells provided a major breakthrough in 
stem cell research2.  Yamanaka hypothesize that transcription factors playing important roles in the 
maintenance of hESC identity also have pivotal roles in the     induction of pluripotency in somatic cells.  
The research group identified numerous factors that are differentially expressed in hESCs in comparison 
to adult stem cells.  By performing detailed comparative analysis, they defined four key transcription 
factors, namely Oct3/4, Sox2, c-Myc, and Klf4, that are essential to the reprogramming of somatic cells.  
This landmark finding lead to the realization of a long awaited scientific dream that adult somatic cells 
can be reprogrammed into induced stem cells and perhaps be used for therapeutic purposes.   
Despite the efforts of Yamanaka in pioneering iPSC technology, several limitations immediately 
became apparent3.  The transgenes used for reprogramming were based on retroviral vectors with      
random insertion into the host genome, allowing for possible interference with the endogenous gene 
structure that could result in undesirable insertional mutations. Furthermore, the lack of complete control 
of transgene expression could result in tumorigenesis.  Several solutions have been explored to address 
these issues including the use of cell-penetrating recombinant proteins for reprogramming cells.4,5   
Initial studies exploring cellular reprogramming with Oct3/4, Sox2, c-Myc, and Klf4, have led way 
to the discovery of a multitude of additional transcription factors that can reprogram iPSCs and in some 
cases alter the eventual differentiation of cells.6,7  Alterations in chromatin structure affecting epigenetic 
regulation are important, dynamic regulators of global genetic expression in iPSCs but remain an       
uncharted territory8  Disruption of tumor suppressor p53 or cell-cycle checkpoint inhibitors (e.g. p14/
ARF, p21) can improve iPSC generation, however are also involved in carcinogenesis.9-12   
Human iPSCs have been generated from fibroblasts, keratinocytes and CD34+ human peripheral 
blood cells13,14.  Recent studies have indicated that cell type and culture environment can affect iPSC 
generation.  While certain cell types may prove to be easier to extract cells from, such as fibroblasts 
from a skin biopsy, other cell types may be more effective for tissue development.  Development of iP-
SCs from keratinocytes show lower rates of transgene retroviral insertion than fibroblasts thus        al-
lowing for more regulated control of cell genetics.13  The low efficacy of iPSC generation in vitro also 
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remains an important challenge for the  generation of significant tissue yields.   
Evaluation of generated iPSCs for therapeutic efficacy and tumor formation is necessary prior to 
implantation in patients.  In this regard, animal models will be important to assess germline transmission 
of iPSCs and cell incorporation into patient tissue.  Furthermore, animal models prior to clinical         
development will be important to screen for the formation of teratoma tumor masses from                   
undifferentiated iPSCs and patient immune reaction from iPSCs containing foreign antigens15.           
The microenvironment of stem cell plays an important role in the regulation of quiescence and           
differentiation.  However, animal models do not fully encompass human microenvironments and   evalu-
ation of a biological mechanism for iPSCs engrafted for disease treatment will be important to   deter-
mine therapeutic efficacy. 
Generation and application of iPSCs to human disease 
 
Cellular delivery of iPSCs to patients remains a crucial technical limitation, which has driven inves-
tigation into tissue engineering technologies.  While certain therapies will suffice with single, direct im-
plantation of iPSCs (e.g. Parkinson’s disease), other approaches may     require multi-site cell delivery 
(e.g. spinal cord injury).  Ex vivo tissue engineering has emerged as a potential solution for artificial tis-
sue formation and organogenesis16.  Extracellular matrices (ECM) composed of biocompatible materials 
in combination with pluripotent cells and specific culturing conditions have been suggested as scaffolds 
for organogenesis.  Technologies such as inkjet printing of collagen matrices, individual live cells, or 
stem cell growth factor have been used to pattern and generate custom 3D tissues.17-19  Decellularization 
of endogenous cells from tissues in order to leave an ECM template where iPSCs can be added to      
regenerate cells has also been pursued in various organs including, heart, liver, kidney, pancreas, and 
intestine.20,21  The role of hypoxia in regulating stem cells has emerged as an important facet of          
pluripotency and is actively being investigated.22  Explanted microvasculature beds serving as scaffolds 
for large tissue formation have also been explored to overcome hypoxic environments limiting iPSC  
engraftment.23 
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A plethora of applications for iPSCs has been suggested, including tissue regeneration for a         
congenital malformations, degenerative disorders, traumas, and genetic defects.  Therapeutic efficacy of 
hESCs has been demonstrated experimentally in animal models of spinal cord injury24, retinal disease25, 
Parkinson’s disease.26  In addition, the first FDA-approved stem cell therapy in humans was recently 
approved for spinal cord injury.27  Sponsored by Geron, Phase I trials for complete thoracic  injury will 
be performed using hESCs and have recruited the first patients in October 2010.  Disease-specific iPSCs 
generated from patient tissues can provide new insights into the pathophysiology of   various complex 
human diseases that currently lack effective models.  Although extensive literature   supports the devel-
opment of stem cell therapies, results should be scrutinized diligently in order to    provide the best qual-
ity of patient care.   
  Despite the remarkable potential for iPSCs, and the emergence of this exciting and rapidly         
expanding field, a variety of technical challenges remain.  Historical evidence has suggested that       
biotechnology takes approximately 10-15 years until the development of realizable therapies.28  While 
genetic engineering methods were discovered in the 1970s, FDA approval of insulin came in 1982 and 
was not widely available until the 1990s.  Advancements in iPSC technologies will continue to develop 
with effort from a cadre of new researchers, challenge grants, and national initiatives.  It is foreseeable 
that physicians in the near future will utilize stem cell therapies to treat many of the deleterious diseases 
currently incurable. 
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